PainReform (PRFX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PainReform Ltd. reported promising initial results from its Phase 3 trial of PRF-110, highlighting its potential to significantly reduce post-surgical pain within the first 48 hours after bunionectomy surgery. However, challenges remain as data for the following 24-hour period is currently unclear. The company is working to address these data issues to provide a comprehensive analysis of PRF-110’s efficacy.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
